Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat
Abstract Hypertension plays an important role in the development and progression of chronic kidney disease. Studies to date, with mineralocorticoid receptor antagonists (MRA), have demonstrated varying degrees of results in modifying the development of renal fibrosis. This study aimed to investigate...
Main Authors: | Catherine J. Leader, Darren J. Kelly, Ivan A. Sammut, Gerard T. Wilkins, Robert J. Walker |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-05-01
|
Series: | Physiological Reports |
Subjects: | |
Online Access: | https://doi.org/10.14814/phy2.14448 |
Similar Items
-
Novel role of spironolactone in the therapy of resistant hypertension: Spironolactone and resistant hypertension
by: Dragojević-Simić Viktorija, et al.
Published: (2019-01-01) -
Analysis of spironolactone polymorphs in active pharmaceutical ingredients and their effect on tablet dissolution profiles
by: Renata Cunha de Resende, et al. -
Spironolactone-Induced Agranulocytosis: A Case Report
by: Shu-Hwa Hsiao, et al.
Published: (2003-11-01) -
Anti-Fibrosis Effect of Relaxin and Spironolactone Combined on Isoprenaline-Induced Myocardial Fibrosis in Rats via Inhibition of Endothelial–Mesenchymal Transition
by: Jiejie Cai, et al.
Published: (2017-03-01) -
Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change
by: Sudeep R. Aryal, et al.
Published: (2021-09-01)